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Abstract
ARDS is particularly characterized by pulmonary edema caused by an increase in pulmonary capillary permeability.
It is considered that limiting pulmonary edema or accelerating its resorption through the modulation of fluid
intake or oncotic pressure could be beneficial. This review discusses the principal clinical studies that have made it
possible to progress in the optimization of the fluid state during ARDS. Notably, a randomized, multicenter study
has suggested that fluid management with the goal to obtain zero fluid balance in ARDS patients without shock
or renal failure significantly increases the number of days without mechanical ventilation. On the other hand, it is
accepted that patients with hemodynamic failure must undergo early and adapted vascular filling. Liberal and
conservative filling strategies are therefore complementary and should ideally follow each other in time in the
same patient whose hemodynamic state progressively stabilizes. At present, although albumin treatment has been
suggested to improve oxygenation transiently in ARDS patients, no sufficient evidence justifies its use to mitigate
pulmonary edema and reduce respiratory morbidity. Finally, the resorption of alveolar edema occurs through an
active mechanism, which can be pharmacologically upregluated. In this sense, the use of beta-2 agonists may be
beneficial but further studies are needed to confirm preliminary promising results.
Introduction
The ventilatory treatment of acute respiratory distress syn-
drome (ARDS) has greatly improved in recent years. Dur-
ing the same period, numerous nonventilatory therapies
have been evaluated. Among them, modulation of fluid
status and plasmatic oncotic pressure in patients have
been the objects of studies–some promising, others disap-
pointing in their physiological effects and outcome. ARDS
is particularly characterized by pulmonary edema caused
by an increase in pulmonary capillary permeability. In the
early phase of ARDS, an associated septic state is usually
responsible for hypovolemia. At this stage, hemodynamic
optimization by early and adapted fluid loading has proven
its prognostic value [1] and a fluid restriction strategy can
result in hemodynamic aggravation and dysfunctions of
associated organs, determining the mortality of patients
with ARDS [2]. Subsequently, hemodynamic stabilization
is generally associated with a resumption of diuresis and a
decrease in body weight. Passage from one phase to
another often is complex and difficult to distinguish but it
is probably by identifying the transition between these two
phases that one can detect the moment when a strategy of
optimization of fluid balance on the restrictive side is
possible. After a reminder on the physiopathologic bases,
this review will present the principal clinical studies that
have made possible to progress in the optimization of the
fluid status during ARDS.
The Consequences of Pulmonary Edema During
ARDS
Even if pulmonary edema is only, in certain aspects, the
reflection of the extent of alveolocapillary barrier lesions, it
nevertheless has an impact on respiratory function at sev-
eral levels [3]. An increase in pulmonary water triggers an
early reduction in pulmonary compliance, which is
responsible for an increase in respiratory work. At the
alveolar edema stage, the intrapulmonary shunt is respon-
sible for hypoxemia. The edema interacts with mechanical
ventilation to facilitate pulmonary inflammation by ren-
dering the lung heterogeneous on a ventilatory level, alter-
ing the surfactant and worsening alveolocapillary barrier
lesions. Finally, edema is one of the principal determinants
of pulmonary arterial hypertension, not only due to
hypoxemia but also due to the pulmonary vascular com-
pression that it triggers.
Thus, any attempt to reduce edema can potentially
have beneficial effects on respiratory function and even-
tually outcome. However, the data that point to the prog-
nostic role of the quantity of edema fluid in patients with
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provided the original work is properly cited.ARDS or at risk of ARDS are very limited. In 1987,
Simmons et al. observed that the evolution of body
weight and fluid balance in ARDS patients [4] was corre-
lated with outcome but without establishing a cause and
effect relationship between them. Similarly, the prognos-
tic role of the quantity of lung water has been suggested.
Recently, Sakka et al. [5] retrospectively analyzed 373
intensive care unit (ICU) patients and found that the
maximum quantity of lung water measured was a predic-
tive factor for outcome. However, the prognostic effect of
the quantity of edema fluid, measured by thermodilution,
w a sn o tf o u n di np a t i e n t sp r e s e n t i n gA R D Si nt h i ss t u d y
[5]. Conversely, lung water amount indexed with pre-
dicted body weight measured on day 1 of ARDS was
found to be predictive of death in another study [6]. By
definition, ARDS patients have severe pulmonary edema
in the region of 15 to 20 ml.kg
-1 of body weight [7,8] and
it is probable that other factors, extrapulmonary, will
h a v eam o r em a r k e dp r o g n o s t i c impact. It should there-
fore be remembered that the degree of hypoxemia is a
controversial prognostic factor during ARDS [9,10].
All in all, it makes sense to consider that limiting pul-
monary edema or accelerating its resorption could be
beneficial. However, even the prognostic role of the
quantity of pulmonary edema fluid remains uncertain.
ARDS: Lesional or Hemodynamic Edema?
Under physiologic conditions, there is a transfer of fluid
from the capillary lumina toward the interstitium. In fact,
on the one hand, the endothelium presents some perme-
ability, the consequences of the forces acting on both
sides of the endothelium favor an extravasation of fluid
[11]. Fluid flux through the pulmonary endothelium is
quite correctly estimated by Starling’se q u a t i o n ,w h i c h
expresses the fact that net filtration flux is the product of
the hydraulic conductance of the exchange surface bar-
rier by effective filtration pressure. The equation is
expressed as follows: Jv = K [(Pc - Pi) - S (πc-πi)], where
Jv is the flow of fluid through the capillary wall, K is the
capillary hydraulic filtration coefficient reflecting
endothelial water permeability, Pc is capillary hydrostatic
pressure, Pi is interstitial hydrostatic pressure, S is the
oncotic reflection coefficient, πc is the capillary oncotic
pressure, and πi is the interstitial oncotic pressure. The
first part of the equation represents the hydrostatic pres-
sure gradient, which tends to produce a flow of fluid out
of the vessels. The second part represents the oncotic
pressure gradient, which opposes this transudation of
fluid. The influence of oncotic pressure on fluid flux
through the endothelium is modulated by the oncotic
reflection coefficient (S), which represents the permeabil-
ity of the endothelium to oncotically active substances.
Schematically, two principal mechanisms can work
toward an increase in pulmonary water and possibly
alveolar flooding: on the one hand, an increase in pulmon-
ary microvascular pressure and on the other hand, an
increase in alveolocapillary barrier permeability. During
ARDS, an increase in endothelial permeability is a funda-
mental element in the formation of pulmonary edema
[12]. On a hydrodynamic level, the capillary hydraulic fil-
tration coefficient increases and the reflection coefficient
of oncotically active substances diminishes or even goes to
nearly zero in certain zones. Thus, the oncotic pressure
gradient, which normally opposes the formation of edema,
is little or no longer effective. Consequently, a given aug-
mentation in hydrostatic pressure will trigger a greater
augmentation in fluid efflux if alveolocapillary barrier per-
meability is increased. This has been well illustrated in
experimental studies by Guyton [13], showing that edema
forms faster and at a lower hydrostatic pressure threshold
when one has first damaged the alveolocapillary barrier
before progressively increasing the left atrium pressure.
Moreover, other experimental studies have shown that
even a modest decrease in pulmonary capillary pressure by
vasodilatation or early reduction of volemia in a lesional
edema model can limit the formation of pulmonary edema
[14-16].
Clinically, even if the presence of pulmonary artery
occlusion pressure (PAOP) inferior to 18 mmHg has been
defined for a diagnosis of increased pulmonary permeabil-
ity edema, a potential role of hydrostatic forces is not
excluded in ARDS. First, PAOP underestimates capillary
filtration pressure, especially in ARDS where the pulmon-
ary venous resistance is increased [17,18]. Second, in case
of increased alveolocapillary permeability, the critical
hydrostatic pressure above which pulmonary edema will
develop will be lower than in the case of normal lung per-
meability. If the capillary hydraulic filtration coefficient is
doubled, critical hydrostatic pressure will only be
10 mmHg. The notion that there is no normal capillary
pressure in case of permeability edema constitutes a theo-
retical justification for limiting pulmonary filtration pres-
sure in case of increased permeability pulmonary edema
or in a patient at risk and therefore for measuring or esti-
mating capillary pressure which is a fairly true reflection.
Most clinical studies have shown that the majority of
patients with ARDS have a PAOP that is superior to criti-
cal filtration pressure values when the barrier is damaged
(Table 1). Among the 1,000 patients enrolled in a recent
randomized, controlled study [19], 29% had a PAOP above
18 mmHg while cardiac index was normal or high, sug-
gesting that high filling pressures observed were not the
result of congestive heart failure. Knowing that the PAOP
is inferior to capillary hydrostatic pressure, one can sup-
pose that these patients more often will have capillary
pressure that is beyond critical pressure.
One can understand the potential interest in limiting
pulmonary microvascular pressure during the period that
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ficult to consider in practice for several reasons. The first
is that in the early phase of inflammatory pulmonary
aggression when the edema is developing, therapeutic
strategy is usually oriented toward systemic hemody-
namic recovery, associating volume resuscitation and
vasopressors with the quite contradictory goal to reduce
pulmonary capillary pressure. The second reason is the
difficulty of measuring or evaluating pulmonary capillary
filtration pressure. Some factors, such as vasoplegia and
hypovolemia, combine to diminish pulmonary capillary
pressure, whereas the local production of vasoconstrictive
mediators or myocardial depression can increase it. In
addition, effective filtration pressure is the resulting com-
plex of venous, capillar and arteriolar pressures, all three
of which can be affected by vasomotor mediators with
contradictory effects.
All in all, maintaining a low pulmonary capillary pres-
sure is understandable, especially early, during the phase
where permeability is increased. However, considering it
as a therapeutic objective is difficult, because correction
of hypovolemia is mandatory and measuring the true
capillary pressure is difficult.
Resorption and Drainage of Pulmonary Edema
As we have seen, ARDS is particularly characterized by
pulmonary edema. The part of the interstitial water that
is in excess and that will not flood the alveoli is drained
by the lymphatic network. The fluid that is not drained
by the lymphatic network–because it is saturated–accu-
mulates in the loose peri-bronchovascular conjunctive
tissue of the hila, which is the first accumulation site in
pulmonary edema. These zones have at the same time
very low resistance to fluid flux and major compliance.
Thus, because interstitial pressure remains low, resorp-
tion of interstitial edema is little or not at all produced by
pulmonary vascular resorption with the pressure remain-
ing in favor of transudation of the vascular sector toward
the interstitium. On the other hand, interstitial drainage
will depend on the capacity of lymphatic flow to increase
as well as the capacity of the perihilar tubes to drain into
the mediastinum and the interstitial edema to evacuate
toward the pleura and then the lymphatic system. Edema
drainage will therefore be increased if right atrial pressure
decreases and if pleural pressure is low.
Once in the alveoli, the water is absorbed from the
alveoli toward the interstitium by active transepithelial
ionic migration, which creates an osmotic gradient lead-
ing to water reabsorption toward the interstitium [20].
This water then goes into the interstitial edema drainage
circuit. Thus, alveolar edema resorption is not per-
formed by communicating vessels with pulmonary circu-
lation. During ARDS, active transport of ions and fluid
by the epithelium is altered due to rupture of the alveo-
locapillary barrier and epithelial cell dysfunction. Water
reabsorption requires that the fluid leak first be reduced
not only by reduction of endothelial permeability but
also possibly by modifications in epithelial cell form,
making the epithelium more solidly impermeable.
Alveolar fluid clearance is altered in most patients with
ARDS, so maintenance of normal clearance or its
increase is reported to be associated with better out-
come [21].
Overall, one can theoretically improve interstitial pul-
monary edema clearance and facilitate edema prevention
mechanisms by diminishing both central venous pres-
sure and pleural pressure. Parallel stimulation of alveolar
edema resorption toward the interstitium could be
complementary.
Fluid Restriction and Diuretics: Clinical Studies
and Practical Consequences
From what we have seen above, even if it is possible that
limitation of pulmonary capillary pressure and facilita-
tion of edema drainage by fluid restriction could limit
the amount of lung edema or facilitate its elimination, it
is not known if there is a clinical interest in diminishing
p u l m o n a r ye d e m a .W et h e r e f o r ew i l ls e et h a tt h ec u r -
rent data in the literature does not make it possible to
establish that the beneficial effects of fluid restriction
have an effect on pulmonary function.
In addition to ventilatory or inotropic therapies, one
can theoretically reduce capillary pressure in two man-
ners: by diminishing the volemia or by vasodilitating the
pulmonary vessels. Selective pulmonary vasodilatation,
in particular by inhaled nitric oxide (NO) or prostaglan-
dins, has been the object of experimental studies in
increased permeability pulmonary edema models. Some
have reported that a reduction in pulmonary water or
endothelial permeability could be connected to a
decrease in capillary filtration pressure [16]. However,
most of the clinical studies in ARDS patients have only
shown modest effects by these drugs on pulmonary
Table 1 Mean values for mean pulmonary arterial
pressure (MPAP), pulmonary capillary pressure (PCP), and
pulmonary artery occlusion pressure (PAOP) in several
clinical studies that studied these parameters in ARDS
patients
n MPAP PCP PAOP Reference number
1,000 na na 15.6 ± 0.4 [19]
10 28 ± 1 17 ± 1 13 ± 1 [22]
18 34 ± 2 25 ± 1 17 ± 1 [23]
7 2 7±3 1 5±1 1 0±1 [ 2 4 ]
15 40 ± 2 27 ± 2 22 ± 1 [46]
8 3 9±2 2 8±2 1 5±1 [ 4 7 ]
na = not available.
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dies have not reported prognostic benefit with the sys-
tematic use of inhaled NO in cases of acute lung injury
or ARDS [25].
Fluid restriction that is more or less associated with a
diuretic treatment makes it possible to reduce both pul-
monary capillary pressure and central venous pressure.
The problem with fluid restriction is that it often is dif-
ficult to perform because of the often precarious hemo-
dynamic state of such patient s .U n t i lr e c e n t l y ,o n l ya
few prospective studies had been undertaken and have
suggested a reduction in respiratory morbidity with fluid
restriction. In 1990, Humphrey et al. [26] suggested that
interventional reduction of PAOP in ARDS patients
improved mortality. However, the study presented
numerous limitations. In a very limited population stu-
died retrospectively, the authors showed that in patients
whose PAOP could be reduced by 25%, mortality was
lower than in those whose PAOP could not be lowered.
No link between PAOP reduction and outcome could
be established. In 1992, Mitchell et al. [8] performed a
randomized study of 101 ICU patients. In 52 patients,
hydration was based on the measurement of extravascu-
lar lung water by double dilution and 49 patients were
monitored by pulmonary arterial catheter and PAOP. In
the group monitored by extravascular lung water mea-
surement, hydration strategy was based on a restriction
of fluid intake associated with the use of vasopressors if
extravascular lung was superior to 7 ml.kg
-1 or on pre-
ferential filling in case of low extravascular lung water,
whereas in the other group, the PAOP objective was
10 mmHg if the hemodynamic state was normal and
18 mmHg in case of hypotension. In patients with
higher PAOP, they used vasopressors or vasodilatators
depending on blood pressure. Fluid loading was used in
patients with lower PAOP. The strategy based on lower-
ing extravascular lung water resulted in a shorter dura-
tion of both ventilation and ICU stay than the PAOP
strategy. The cumulated fluid result for the first 3 days
was + 2 liters in the “PAOP” group, whereas it was zero
in the “extravascular lung water” group in which PAOP
also significantly diminished. Extravascular lung water
diminished by 25% in the “extravascular lung water”
group, whereas it did not change in the other group,
suggesting that it was really fluid restriction that acted
on extravascular lung water reduction and that it influ-
enced outcome. There was no increase in vasopressor
requirements.
More recently, a randomized, multicenter study evalu-
ated a strategy of fluid restriction that was more or less
associated with diuretic treatment prescribed in the
absence of hypotension and renal failure in patients with
acute lung injury or ARDS [19]. Patients were included
in the study approximately 48 hours after admission to
the ICU. The decision to submit patients to fluid loading
or to diuretic treatment depended on the presence of oli-
g u r i aa n dt h el e v e lo fc e n t r a l venous pressure (CVP) of
PAOP. Schematically, the goal was to obtain a CVP of 8
mmHg or less in the “conservative-strategy” group or 14
mmHg in the “liberal-strategy” group. In the patients
monitored by pulmonary arterial catheter, the objectives
of PAOP were 12 mmHg in the conservative-strategy
group and 18 mmHg in the liberal-strategy group. The
protocol was applied for 7 days after inclusion of the
patient but was not applied in cases of hypotension. The
conservative strategy resulted in zero fluid in 7 days,
whereas the fluid results in the liberal-strategy group
were +6 liters over 7 days. The conservative strategy dis-
creetly improved oxygenation in patients and increased
the number of days without ventilation (14.6 ± 0.5 vs.
12 ± 0.5; p < 0.001) but did not influence mortality at 60
days, which was the principal goal of the study. This
study confirmed the impression that limiting the fluid
intake of patients with isolated respiratory failure can
limit respiratory morbidity without aggravating other
organ dysfunctions. However, the exclusion of hemody-
namically unstable patients or patients with renal failure
makes it impossible to generalize these results or to cre-
ate a “gold standard” for management of the fluid status
of every ARDS patient. In addition, the absence of an
effect on mortality reminds us that the management of
fluid intake in ICU patients does not boil down to being
liberal or conservative. In most patients, ARDS is
described within the framework of an early and general-
ized systemic inflammation that is responsible for hemo-
dynamic dysfunction. At this stage, hemodynamic
restoration based on early fluid administration constitu-
tes one of the cornerstones for improving outcome [1]. It
is only once the initial phase of instability has passed that
a reasonable policy of fluid intake aimed at zero fluid can
contribute to reducing the duration of ventilation and
ICU stay [27]. The importance of a “biphase” fluid strat-
egy was recently illustrated by a retrospective study that
included 212 patients presenting acute lung injury (ALI)
complicating septic shock [2 8 ] .I nt h i ss t u d y ,t h en o n -
performance of early adapted fluid administration and
t h ea b s e n c eo fan e g a t i v ef l u i db a l a n c ed u r i n gam i n i -
mum of the first 2 consecutive days within the 7 days fol-
lowing the occurrence of septic shock were independent
mortality factors in multivariate analysis. Along these
lines, the Surviving Sepsis Campaign [29] recommends a
conservative fluid strategy in patients with ARDS or ALI
and in the absence of shock. Other recent studies have
stressed the influence of fluid balance on outcome
[30,31]. However, their design does not make it possible
to confirm if an interventional strategy, such as that of
t h eF A C T Ts t u d y[ 1 9 ] ,i n f l u e n c e st h eo u t c o m eo fA R D S
patients. According to the literature, the beneficial effect
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spiratory mechanisms. Thus, the patients treated with a
conservative strategy in the FACTT study [19] had better
neurological status - perhaps because the patients were
desedated earlier because of better respiratory status, per-
haps because they had less severe cerebral edema. More-
over, the patients with conservative treatment received
fewer transfusions whose potentially deleterious role is
well known in intensive care [32]. A simplified version of
the algorithm used in the FACTT study was published by
the ARDS Network and discussed in a recent review on
the subject [33].
Modulation of Oncotic or Osmotic Pressure: The
Effects of Administering Albumin or Hypertonic
Saline
From a hemodynamic point of view, in case of a
decrease in plasmatic oncotic pressure, which is clini-
cally illustrated by hypoprotidemia/hypoalbuminemia,
pulmonary edema forms at a lower hydrostatic pressure
because the oncotic pressure gradient between plasma
and the interstitium decreases. Therefore, experimen-
tally, whereas the pulmonary edema begins to develop
at a pressure of 24 mmHg when oncotic pressure is nor-
mal, it begins at 11 mmHg when it is reduced [13].
Hypoprotidemia therefore facilitates the development of
hydrostatic pulmonary edema. This is potentially impor-
tant in ICU patients in whom hemodiluation and cata-
bolism associate to diminish protidemia. However, the
importance of oncotic pressure in the limitation of flux
is only conceivable if the barrier is intact. In case of
endothelial lesions, an interstitial edema will be all the
richer in proteins than the plasma, theoretically limiting
the interest of increasing the plasmatic oncotic pressure.
Thus, in animal models, an increase in oncotic pressure
during the early phase of a lesional edema will not limit
the formation of edema [14].
On analyzing a cohort of 455 septic patients with a risk
of ARDS, Mangialardi et al. [34] found that hypoprotide-
mia was an independent predictor of the occurrence of
ARDS. Subsequently, the same team [35] evaluated the
interest of a strategy of diuretic treatment associated with
albumin filling in ARDS patients with a protidemia infer-
ior to 50 g/l. Of the 37 patients included in the study, 19
received an association of albumin (75 g/d) and furose-
mide for 5 days and 18 received placebos. When the proti-
demia was superior to 60 g/l in the treated group, the
treatments were replaced by placebos. Continuous infu-
sion of furosemide was adjusted to obtain a weight loss of
at least 1 kg/d without exceeding 8 mg/h of furosemide.
The patients in the treated group presented a PaO2/FiO2
ratio that was slightly and transitionally better than that of
the placebo group, without other beneficial or deleterious
effects, particularly on renal function. In a second study
[36] to distinguish the effects of albumin and diuretics, the
same authors randomized 40 patients; 20 received furose-
mide alone and the other 20 received furosemide and
albumin (75 g/d) for 3 days. When protidemia was super-
ior to 80 g/l in the treated group, albumin was replaced
with a placebo. Albuminemia increased by 13 g/l in the
albumin + furosemide group, reaching 30 g/l at the end of
treatment and increased by 3 g/l in the furosemide alone
group, reaching 20 g/l at the end of treatment. Once
again, the effects can be summarized by a discrete
improvement in oxygenation when albumin was asso-
ciated with diuretic treatment compared with diuretic
treatment alone. A large randomized study [37] demon-
strated that volume therapy using albumin was equivalent
to volume therapy using saline in ICU patients. At this
time, the very limited clinical data do not make it possible
to recommend the administration of albumin with the
goal to improve pulmonary function and respiratory mor-
bidity in ARDS patients.
The use of hyperosmolar filling solutions, such as hyper-
tonic saline, could have the advantage, due to the limited
amount of fluid administered, of limiting the development
of pulmonary edema in case of an increase in the alveolo-
capillary barrier. Moreover, the use of hypertonic solutions
has limited pulmonary injury after hemorrhagic shock in
experimental models by improving splanchnic output and
reducing the adhesion and cytotoxicity of neutrophils
compared with the use of isotonic solutions [38,39]. In
clinical practice, the potential interest of hypertonic resus-
citation has been investigated in patients with traumatic
hypovolemic shock. In a randomized study that included
422 patients, evolution toward ALI was less frequent when
patients had received fluid loading with hypertonic saline/
dextran than with normal saline [40]. However, in a recent
randomized study, including 853 patients, fluid loading
with hypertonic saline or hypertonic saline/dextran neither
reduced mortality nor prevented ARDS occurrence com-
pared with normal saline resuscitation [41].
Roch et al. [42] compared in a porcine model of
hemorrhagic shock the effect of isotonic and hypertonic
solutions on the occurrence of pulmonary lesions and
on inflammation according to precise hemodynamic cri-
teria. The use of hypertonic saline did not exert a pre-
ventive effect on the appearance of ALI and pulmonary
edema after hemorrhage in this study. Those authors
even observed a deleterious effect with the prior use of
hypertonic saline before performing experimental ische-
mia-reperfusion by clamping the pulmonary arteries
[43]. This effect appeared to be independent of the
hemodynamic effects of saline but was more probably
linked to a direct effect on alveolocapillary barrier
permeability.
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Complementary Objective
This therapeutic aspect does not strictly imply manipu-
lation of fluid balance in patients. However, it deserves
to be mentioned because it clearly shows that resorption
of alveolar edema does not occur by manipulation of
vascular pressures, but rather by stimulation of active
water transport from the alveoli toward interstitium,
which would be complementary to strategies favoring
the draining of interstitial edema.
Despite severe epithelial lesions, alveolar clearance is
usually pharmacologically stimulable. Several experimental
studies have shown that the exogenous administration of
cAMP agonists, in particular beta-2 agonists, accelerates
the resolution of edema, whatever its nature [44]. The
action of beta-2 agonists principally occurs through an
increase in the quantity and activity of Na/K pumps in the
basal membrane and sodium canals in the pneumocyte api-
cal membrane whose effect is to increase the sodium gradi-
ent between the alveoli and the interstitium and therefore
the absorption of water. A recent clinical study [45] showed
that the administration of IV salbutamol at a dose of 15 μg/
kg/h for 7 d in ARDS patients made it possible to diminish
the quantity of pulmonary water measured by transpul-
monary thermodilution without affecting oxygenation,
duration of mechanical ventilation, or outcome. However,
it was a preliminary study that included only 40 patients.
Conclusions
Fluid management with the goal to obtain zero fluid
balance in ARDS patients without shock or renal failure
significantly increases the number of days without
mechanical ventilation [19]. On the other hand, patients
with hemodynamic failure must receive early and
adapted fluid resuscitation [1]. Liberal and conservative
fluid strategies are therefore complementary and should
ideally follow each other in time in the same patient
whose hemodynamic state progressively stabilizes. At
present, albumin treatment does not appear to be justi-
fied for limitation of pulmonary edema and respiratory
morbidity. Finally, the resorption of alveolar edema
occurs through an active mechanism, which can be
pharmacologically upregluated. In this sense, the use of
beta-2 agonists may be beneficial, but further studies are
needed to confirm preliminary promising results.
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